Fenglan Pu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fenglan Pu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Jian-Ping Liu
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, China
3 shared publications - Chen Shen
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Lingyao Kong
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Xiaowen Zhang
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
2 shared publications - Bertrand Granado
Université Pierre et Marie Curie
1 shared publication Chen Shen
1 shared publication
Latest Publications
- Open Access
- 8 January 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2300302
Fermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials
To evaluate the efficacy, effectiveness and safety of fermented Ophiocordyceps sinensis mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI). Randomized controlled trials were searched from four Chinese and four English electronic databases and three clinical trial registries up to July 2023. Methodological quality was assessed by using the Cochrane risk-of-bias tool 2.0. Risk difference (RD) or risk ratio (RR) and mean difference (MD) were calculated along with the 95% confidence intervals (CIs). Fourteen trials testing three types of FOSM products (Bailing, Zhiling, and Jinshuibao capsules) involving 1271 participants injected contrast agents were included. For the risk of bias, all trials were rated as some concerns. Compared with routine preventive procedure (RPP) (saline hydration and alprostadil), FOSM products plus RPP showed beneficial effects in reducing the incidence of CA-AKI (14.62% and 5.35%, respectively; RD -0.06, 95% CI -0.09 to -0.03). Subgroup analysis showed that Bailing/Jinshuibao plus RPP demonstrated lower incidence of CA-AKI compared to RPP. However, there was no statistically significant difference between Zhiling with RPP and RPP in the incidence of CA-AKI. Additionally, only when FOSM products were taken before injection of the contrast, it was superior to RPP in reducing the incidence of CA-AKI. There was no statistical difference in adverse events between these two groups. Low certainty evidence suggests that preventive oral use of FOSM products as an adjuvant agent was safe and might decrease the incidence of CA-AKI. However, high-quality placebo-controlled trials are needed to confirm its benefit.
- 8 January 2024
- Published by Taylor & Francis in Renal Failure
- Vol. 46 (1) , 2300302
Open AccessFermented Ophiocordyceps sinensis mycelium products for preventing contrast-associated acute kidney injury: a systematic review of randomized controlled trials
To evaluate the efficacy, effectiveness and safety of fermented Ophiocordyceps sinensis mycelium (FOSM) products for preventing contrast-associated acute kidney injury (CA-AKI). Randomized controlled trials were searched from four Chinese and four English electronic databases and three clinical trial registries up to July 2023. Methodological quality was assessed by using the Cochrane risk-of-bias tool 2.0. Risk difference (RD) or risk ratio (RR) and mean difference (MD) were calculated along with the 95% confidence intervals (CIs). Fourteen trials testing three types of FOSM products (Bailing, Zhiling, and Jinshuibao capsules) involving 1271 participants injected contrast agents were included. For the risk of bias, all trials were rated as some concerns. Compared with routine preventive procedure (RPP) (saline hydration and alprostadil), FOSM products plus RPP showed beneficial effects in reducing the incidence of CA-AKI (14.62% and 5.35%, respectively; RD -0.06, 95% CI -0.09 to -0.03). Subgroup analysis showed that Bailing/Jinshuibao plus RPP demonstrated lower incidence of CA-AKI compared to RPP. However, there was no statistically significant difference between Zhiling with RPP and RPP in the incidence of CA-AKI. Additionally, only when FOSM products were taken before injection of the contrast, it was superior to RPP in reducing the incidence of CA-AKI. There was no statistical difference in adverse events between these two groups. Low certainty evidence suggests that preventive oral use of FOSM products as an adjuvant agent was safe and might decrease the incidence of CA-AKI. However, high-quality placebo-controlled trials are needed to confirm its benefit.
- 24 June 2022
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Cordyceps preparations for preventing contrast-induced nephropathy: A protocol of systematic review of randomized controlled trials
Review question / Objective: To systematically evaluate the efficacy and safety of cordyceps preparations as a complementary preventive therapy for Contrast-induced nephropathy (CIN). Condition being studied: At present, contrast agents are widely used in diagnostic and interventional radiology examinations worldwide. However, they can affect kidney function and cause a risk of renal impairment. Contrast-induced nephropathy (CIN) is defined as a rise in serum creatinine (SCr) levels by ≥ 25% of baseline or 44 µmol/l from the pre-contrast value within 72 h of intravascular administration of a contrast agent in the absence of an alternative etiology. The incidence of CIN varies widely among studies depending on study population and baseline risk factors, as for high-risk groups such as pre-existing renal insufficiency, diabetes, advanced age, or receiving nephrotoxic agents, the incidence is up to 30–50%. To date, CIN has been the third most common cause of hospital-acquired renal failure, after impaired renal perfusion and nephrotoxic medications, which can lead to longer hospital stay, increased costs and higher mortality.
- 24 June 2022
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Cordyceps preparations for preventing contrast-induced nephropathy: A protocol of systematic review of randomized controlled trials
Review question / Objective: To systematically evaluate the efficacy and safety of cordyceps preparations as a complementary preventive therapy for Contrast-induced nephropathy (CIN). Condition being studied: At present, contrast agents are widely used in diagnostic and interventional radiology examinations worldwide. However, they can affect kidney function and cause a risk of renal impairment. Contrast-induced nephropathy (CIN) is defined as a rise in serum creatinine (SCr) levels by ≥ 25% of baseline or 44 µmol/l from the pre-contrast value within 72 h of intravascular administration of a contrast agent in the absence of an alternative etiology. The incidence of CIN varies widely among studies depending on study population and baseline risk factors, as for high-risk groups such as pre-existing renal insufficiency, diabetes, advanced age, or receiving nephrotoxic agents, the incidence is up to 30–50%. To date, CIN has been the third most common cause of hospital-acquired renal failure, after impaired renal perfusion and nephrotoxic medications, which can lead to longer hospital stay, increased costs and higher mortality.
- Open Access
- 19 October 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 10 (Suppl) , 100798
Traditional Chinese medicine for COVID-19 pandemic and emerging challenges: An online cross-sectional survey in China
- 19 October 2021
- Published by Elsevier in Integrative Medicine Research
- Vol. 10 (Suppl) , 100798
Open AccessTraditional Chinese medicine for COVID-19 pandemic and emerging challenges: An online cross-sectional survey in China
- Open Access
- 1 October 2021
- Published by Elsevier in Journal of Traditional Chinese Medical Sciences
- Vol. 8 (4) , 291-301
Chinese herbal medicine for incomplete immune reconstruction in patients with AIDS undergoing antiretroviral treatment: A systematic review of randomized trials
- 1 October 2021
- Published by Elsevier in Journal of Traditional Chinese Medical Sciences
- Vol. 8 (4) , 291-301
Open AccessChinese herbal medicine for incomplete immune reconstruction in patients with AIDS undergoing antiretroviral treatment: A systematic review of randomized trials